InsidersTradesSigma
Total declarations
Company
▲ Purchases (14 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
14
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-3.3%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Cearnal Martin E. Director active across 1 company, notably Cumberland Pharmaceuticals INC. Cumulatively, 17 reports have been recorded. Split: 14 buys · 0 sell. Total volume traded: €4k. History available since 17 March 2021. The latest transaction was filed on 17 March 2022 (J). Regulator: SEC (Form 4). The full history is free.
Declarations17 total
●
15,000 shares@ US$2.740.045% mcap65.4% of flowCommon StockSEC:0001209191-22-026154:0
90 shares@ US$4.140.0004% mcap0.6% of flowCommon StockSEC:0001209191-22-002447:0
Ideal exit: 28 Aug 2022 (T+270)
90 shares@ US$4.140.6% of flowCommon StockSEC:0001209191-22-002447
Ideal exit: 28 Aug 2022 (T+270)
105 shares@ US$2.670.0003% mcap0.4% of flowCommon StockSEC:0001209191-21-067878:0
Ideal exit: 29 Jul 2022 (T+270)
105 shares@ US$2.670.4% of flowCommon StockSEC:0001209191-21-067878
Ideal exit: 29 Jul 2022 (T+270)
105 shares@ US$2.690.0003% mcap0.4% of flowCommon StockSEC:0001209191-21-063217:0
Ideal exit: 28 Jun 2022 (T+270)
105 shares@ US$2.690.4% of flowCommon StockSEC:0001209191-21-063217
Ideal exit: 28 Jun 2022 (T+270)
105 shares@ US$2.880.4% of flowCommon StockSEC:0001209191-21-058506
Ideal exit: 29 May 2022 (T+270)
105 shares@ US$2.880.0003% mcap0.4% of flowCommon StockSEC:0001209191-21-058506:0
Ideal exit: 29 May 2022 (T+270)
105 shares@ US$3.340.0004% mcap0.5% of flowCommon StockSEC:0001209191-21-055478:0
Ideal exit: 29 Apr 2022 (T+270)
105 shares@ US$3.340.5% of flowCommon StockSEC:0001209191-21-055478
Ideal exit: 29 Apr 2022 (T+270)
105 shares@ US$2.930.5% of flowCommon StockSEC:0001209191-21-051433
Ideal exit: 27 Mar 2022 (T+270)
105 shares@ US$2.930.0003% mcap0.5% of flowCommon StockSEC:0001209191-21-051433:0
Ideal exit: 27 Mar 2022 (T+270)
105 shares@ US$2.910.0003% mcap0.4% of flowCommon StockSEC:0001209191-21-046210:0
Ideal exit: 12 Feb 2022 (T+270)
105 shares@ US$2.910.4% of flowCommon StockSEC:0001209191-21-046210
Ideal exit: 12 Feb 2022 (T+270)
●
2,945 shares@ US$3.220.0097% mcap14.0% of flowCommon StockSEC:0001209191-21-038980:0
●
2,945 shares@ US$3.2214.0% of flowCommon StockSEC:0001209191-21-038980
17 of 17 declarations
About Cearnal Martin E
Cearnal Martin E is an executive at Cumberland Pharmaceuticals Inc.
